Deep learning enables rapid identification of potent DDR1 kinase inhibitors; Reinforced Adversarial Neural Computer for de Novo Molecular Design; Potential 2019-nCoV 3C-like protease inhibitors designed using generative deep learning approaches; Entangled conditional adversarial autoencoder for de novo drug discovery; Adversarial Threshold Neural Computer for Molecular de Novo Design; Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach; Small Molecule Inhibitors of NF-îœ‘ B and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics; Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques; Multicomponent reactions of isocyanides in the synthesis of heterocycles; Recent advances in the synthesis of Fe3O4@ AU core/shell nanoparticles; Shape signatures: new descriptors for predicting cardiotoxicity in silico; Sorting out antibiotics' mechanisms of action: a double fluorescent protein reporter for high-throughput screening of ribosome and DNA biosynthesis inhibitors; Comprehensive computational assessment of ADME properties using mapping techniques; Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors; Exploring the chemogenomic knowledge space with annotated chemical libraries; In silico estimation of DMSO solubility of organic compounds for bioscreening; Kohonen maps for prediction of binding to human cytochrome P450 3A4; New approaches to the treatment of inflammatory disease: focus on small-molecule inhibitors of signal transduction pathways; Are we opening the door to a new era of medicinal chemistry or being collapsed to a chemical singularity? Perspective; Computational mapping tools for drug discovery
